Outcomes in COVID-19 ensitrelvir studies
0
0.5
1
1.5+
All studies 27% 2
255
Improvement, Studies, Patients Relative Risk Viral clearance 35% 2
249
RCTs 27% 2
255
Peer-reviewed 9% 1
227
Early 27% 2
255
Ensitrelvir for COVID-19 c19 early.org/en Mar 2023Favors ensitrelvir Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Mukae (DB RCT) 45%
0.55 [0.37-0.81]
viral load
14 (n)
14 (n)
Improvement, RR [CI] Treatment Control Mukae (DB RCT) 9%
0.91 [0.76-1.08]
improv.
116 (n)
111 (n)
Tau​2 ​ = 0.10, I​2 ​ = 81.4%, p = 0.21
Early treatment 27%
0.73 [0.45-1.19]
0/130
0/125
27% improvement All studies 27%
0.73 [0.45-1.19]
0/130
0/125
27% improvement 2 ensitrelvir COVID-19 studies c19 early.org/en Mar 2023Tau​2 ​ = 0.10, I​2 ​ = 81.4%, p = 0.21
Effect extraction pre-specified (most serious outcome) Favors ensitrelvir
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Mukae (DB RCT) 9%
0.91 [0.76-1.08]
improv.
116 (n)
111 (n)
Improvement, RR [CI] Treatment Control Tau​2 ​ = 0.00, I​2 ​ = 0.0%, p = 0.28
Early treatment 9%
0.91 [0.76-1.08]
0/116
0/111
9% improvement All studies 9%
0.91 [0.76-1.08]
0/116
0/111
9% improvement 1 ensitrelvir COVID-19 recovery result c19 early.org/en Mar 2023Tau​2 ​ = 0.00, I​2 ​ = 0.0%, p = 0.28
Favors ensitrelvir
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Mukae (DB RCT) 45%
0.55 [0.37-0.81]
viral load
14 (n)
14 (n)
Improvement, RR [CI] Treatment Control Mukae (DB RCT) 32%
0.68 [0.56-0.82]
viral time
113 (n)
108 (n)
Tau​2 ​ = 0.00, I​2 ​ = 0.0%, p < 0.0001
Early treatment 35%
0.65 [0.54-0.77]
0/127
0/122
35% improvement All studies 35%
0.65 [0.54-0.77]
0/127
0/122
35% improvement 2 ensitrelvir COVID-19 viral clearance results c19 early.org/en Mar 2023Tau​2 ​ = 0.00, I​2 ​ = 0.0%, p < 0.0001
Favors ensitrelvir
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Mukae (DB RCT) 45%
0.55 [0.37-0.81]
viral load
14 (n)
14 (n)
Improvement, RR [CI] Treatment Control Mukae (DB RCT) 9%
0.91 [0.76-1.08]
improv.
116 (n)
111 (n)
Tau​2 ​ = 0.10, I​2 ​ = 81.4%, p = 0.21
Early treatment 27%
0.73 [0.45-1.19]
0/130
0/125
27% improvement All studies 27%
0.73 [0.45-1.19]
0/130
0/125
27% improvement 2 ensitrelvir COVID-19 Randomized Controlled Trials c19 early.org/en Mar 2023Tau​2 ​ = 0.10, I​2 ​ = 81.4%, p = 0.21
Effect extraction pre-specified (most serious outcome) Favors ensitrelvir
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Mukae (DB RCT) 9%
0.91 [0.76-1.08]
improv.
116 (n)
111 (n)
Improvement, RR [CI] Treatment Control Tau​2 ​ = 0.00, I​2 ​ = 0.0%, p = 0.28
Early treatment 9%
0.91 [0.76-1.08]
0/116
0/111
9% improvement All studies 9%
0.91 [0.76-1.08]
0/116
0/111
9% improvement 1 ensitrelvir COVID-19 peer reviewed studies c19 early.org/en Mar 2023Tau​2 ​ = 0.00, I​2 ​ = 0.0%, p = 0.28
Effect extraction pre-specified (most serious outcome) Favors ensitrelvir
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Mukae (DB RCT) 45%
0.55 [0.37-0.81]
viral load
14 (n)
14 (n)
Improvement, RR [CI] Treatment Control Mukae (DB RCT) 36%
0.64 [0.41-1.00]
viral load
15 (n)
14 (n)
Mukae (DB RCT) 45%
0.55 [0.34-0.90]
viral time
15 (n)
14 (n)
Mukae (DB RCT) 44%
0.56 [0.35-0.92]
viral time
13 (n)
14 (n)
Mukae (DB RCT) 54%
0.46 [0.05-4.38]
viral+
1/12
2/11
Mukae (DB RCT) -10%
1.10 [0.22-5.51]
viral+
3/15
2/11
Mukae (DB RCT) 80%
0.20 [0.01-3.80]
viral+
0/13
2/13
Mukae (DB RCT) 54%
0.46 [0.05-4.53]
viral+
1/14
2/13
Mukae (DB RCT) 54%
0.46 [0.10-2.12]
viral+
2/14
4/13
Mukae (DB RCT) 90%
0.10 [0.01-0.85]
viral+
0/15
4/13
Mukae (DB RCT) 80%
0.20 [0.05-0.75]
viral+
2/14
10/14
Mukae (DB RCT) 63%
0.37 [0.15-0.92]
viral+
4/15
10/14
Mukae (DB RCT) 9%
0.91 [0.59-1.40]
viral+
10/14
11/14
Mukae (DB RCT) -10%
1.10 [0.79-1.55]
viral+
13/15
11/14
Mukae (DB RCT) 9%
0.91 [0.76-1.08]
improv.
116 (n)
111 (n)
Mukae (DB RCT) 17%
0.83 [0.69-0.99]
improv.
114 (n)
111 (n)
Mukae (DB RCT) 32%
0.68 [0.56-0.82]
viral time
113 (n)
108 (n)
Mukae (DB RCT) 44%
0.56 [0.42-0.75]
viral time
113 (n)
108 (n)
Ensitrelvir COVID-19 outcomes c19 early.org/en Mar 2023Favors ensitrelvir
Favors control
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation.
FLCCC and
WCH
provide treatment protocols.
Thanks for your feedback! Please search before submitting papers and note
that studies are listed under the date they were first available, which may be
the date of an earlier preprint.
Submit
